17 Results
Sort By:
Published on August 23, 2022
Researchers for the Translation Genomics Research Institute (TGen) and Temple University have uncovered a link to decreases in an enzyme that is linked to nonalchoholic fatty liver disease (NAFLD). A broad term for a range of conditions, NAFLD is an increasingly common—and potentially deadly—condition caused by an excess accumulation of…
Published on June 28, 2022
Multiple gene variants, including some previously unknown, have been linked to nonalcoholic fatty liver disease (NAFLD) in children. Researchers confirmed that the PNPLA3 gene is associated with the greatest risk for having NAFLD. A different SNP in the gene TM6SF2 was most strongly associated with what percentage of liver cells…
Published on July 21, 2021
A type of RNA methylation that varies between the sexes can help protect the liver from non-alcoholic fatty liver disease (NAFLD), according to a mouse study from the University of California, Los Angeles (UCLA). NAFLD is an umbrella term for a range of liver conditions affecting people who drink little…
Published on March 6, 2024
New research from a Phase IIb pilot study has found that a weekly injection of semaglutide (Wegovy) reduced the amount of fat in the liver by 31% in people infected with HIV who have metabolic dysfunction-associated steatotic liver disease (MASLD). The regimen was also well tolerated noted the researchers who…
Published on November 14, 2022
San Diego-based Lipidio Pharmaceuticals has announced the close of an extension to its Series A financing, bringing the total amount raised to over $20M. The company’s lead program, GDD3898, is in development for the treatment of several conditions associated with excess body fat, including moderate to severe acne and sebaceous…
Published on August 16, 2022
University of Michigan (U-M) Life Sciences Institute scientists have discovered a hormone secreted by fat cells can prevent the growth of liver tumors in mice. The study may give hope for developing therapies against hepatocellular carcinoma (HCC). The findings are published in the journal Cell Metabolism. “The mammalian liver comprises heterogeneous cell types…
Published on June 15, 2022
Nonalcoholic fatty liver disease (NAFLD) is the most common pediatric liver disease, affecting millions of children in the United States. Now researchers demonstrate a connection between NAFLD and diabetes risk. The new findings appear in Clinical Gastroenterology and Hepatology. “This is alarming because type 2 diabetes in youth is a…
Published on September 20, 2021
Promising biomarkers for progression of non-alcoholic fatty liver disease (NAFLD) were found in a study led by researchers at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope. They identified differences in DNA methylation (DNAm) that accurately predicted different stages of liver fibrosis in as many as 94%…
Published on December 10, 2024
A new study has identified two distinct subtypes of metabolic dysfunction-associated steatotic liver disease (MASLD)—formerly known as nonalcoholic fatty liver disease (NAFLD)—a fatty liver disease that can progress to cirrhosis, liver cancer, and other health complications. The disease spans from benign fat accumulation in the liver (steatosis) to its more…
Published on June 5, 2024
A report published in 2023, estimates that over 40% of adults in the U.S. have obesity, defined as a body mass index (BMI) of over 30 kg/m2. While not everyone in this group is unwell, there is no doubt that obesity increases the risk of associated health conditions such as…
Published on September 28, 2023
A multi-center study of metabolic dysfunction-associated steatotic liver disease (MASLD) led by researchers at the University of Michigan has shown genetic variation that contributes to the development of the MASLD, and has identified seven distinct subgroups of the disease that suggest the need to take precision treatment approaches. MASLD, formerly…
Published on September 7, 2023
Gene therapy company Kriya has acquired Tramontane Therapeutics, which is developing such therapies for metabolic and neurodegenerative diseases. Kriya has prioritized Tramontane’s lead program that uses an adeno-associated virus (AAV) vector targeting Fibroblast Growth Factor 21 (FGF2), which has been established as a clinically-validated biological target in Non-alcoholic steatohepatitis (NASH). “People with NASH…
Published on August 17, 2022
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and occurs most often in people with chronic liver diseases, such as cirrhosis caused by hepatitis B or hepatitis C infection. According to the American Cancer Society, the five-year survival rate for patients with localized liver cancer is…
Published on December 17, 2021
Researchers based at Wuhan University in China have discovered a mechanism that drives fatty liver disease. They also presented evidence about a small molecule that can target this mechanism, blocking the disorder’s progression in small and large animals. The team’s results suggest this may point to a promising new therapeutic…
Published on February 6, 2020
ProSciento said today it will combine its predictive screening methodology and clinical protocol with Nordic Bioscience’s biomarker technology in a collaboration designed to improve the diagnosis, prognosis and development of therapeutics for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Under their collaboration—whose value was not disclosed—the companies plan…